Belgium (BE)

Erratum: Correction to: Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis (Human reproduction update (2022) 28 3 (400-416)) (2022) Khattak H, Malhas R, Craciunas L, Afifi Y, Amorim CA, Fishel S, Silber S, et al. Journal article, Erratum Intraoperative robotic-assisted low anterior rectal resection performance assessment using procedure-specific binary metrics and a global rating scale (2022) Gomez Ruiz M, Tou S, Gallagher AG, Cagigas Fernandez C, Cristobal Poch L, Matzel K Journal article Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer (2022) Peddi PF, Fasching P, Liu D, Quinaux E, Robert NJ, Valero V, Crown J, et al. Journal article Time to evolve: predicting engineered T cell-associated toxicity with next-generation models (2022) Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, et al. Journal article, Review article LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al. Journal article Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT (2022) Machowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema DJ, De Wreede LC, Blok HJ, Isaksson C, et al. Journal article Band transport by large Fröhlich polarons in MXenes (2022) Zheng W, Sun B, Li D, Gali SM, Zhang H, Fu S, Di Virgilio L, et al. Journal article PRECLINICAL EFFICACY OF DIRECT AMPK ACTIVATION WITH A NOVEL SMALL MOLECULE-PXL770-FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (2022) Dagorn PG, Buchholz B, Bange H, Blockken L, Moller DE, Hallakou-Bozec S Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) (2022) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution